The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022.

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...

The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...

GSK should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable ...

My Analysis & Recommendation The robust financial performance of GSK in Q3 2023, driven notably by the stellar market debut of Arexvy, lays a promising foundation for 2024.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.